Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Publication Type:

Journal Article


The Lancet infectious diseases, Volume 14, Issue 5, p.388-96 (2014)


2014, Center-Authored Paper, March 2014, Research Trials Office Core Facility - Biostatistics Service, Shared Resources, Specimen Processing Core Facility, Vaccine and Infectious Disease Division


The HVTN 503/Phambili study, which assessed the efficacy of the Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine in South Africa, was stopped when futility criteria in the Step study (assessing the same vaccine in the Americas, Caribbean, and Australia) were met. Here we report long-term follow-up data.